1. Rothschilds, AM, Wittrup, KD (2019). What, Why, Where, and When: Bringing Timing to Immuno-Oncology. Trends Immunol40,12-21.
  2. Kauke, MJ, Tisdale, AW, Kelly, RL, Braun, CJ, Hemann, MT, Wittrup, KD (2018). A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Mol Cancer Ther17,1773-1780.
  3. Chen, TF, Li, KK, Zhu, EF, Opel, CF, Kauke, MJ, Kim, H, Atolia, E, Wittrup, KD (2018). Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcγR Types. J Mol Biol430,1786-1798.
  4. Angelini, A, Miyabe, Y, Newsted, D, Kwan, BH, Miyabe, C, Kelly, RL, Jamy, MN, Luster, AD, Wittrup, KD (2018). Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nat Commun9,1461.
  5. Kelly, RL, Le, D, Zhao, J, Wittrup, KD (2018). Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. J Mol Biol430,119-130.
  6. Green, DJ, O'Steen, S, Lin, Y, Comstock, ML, Kenoyer, AL, Hamlin, DK, Wilbur, DS, Fisher, DR, Nartea, M, Hylarides, MD et al. (2018). CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood131,611-620.